15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.

Usage profile

Descriptive measurement of demographic and clinical variables (central tendency, dispersion and distribution of tendencies) prior to the start of treatment.

Time frame: Initial

Evaluate the security of the treatment

Number and description of adverse effects, analysing the percentage and frequency of withdrawal and treatment suspension due to side effects.

Time frame: Up to 16 weeks

Evaluate the changes in the patient´s quailty of life due to the treatment

Quantified by the average absolute change of the dermatology life quality index (DLQI) score, a questionnaire that measures the effect that the skin disease has on the quality of life of an affected person.

Time frame: Up to 16 weeks

Evaluate the changes in the patient´s quailty of life due to the treatment 2

Quantified by the average absolute changein the visual analog scale of pain, odor and suppuration, a scale used to measure the intensity or frequency of the symptoms related to the pain, odor and suppuration of the disease.

Time frame: Up to 16 weeks

Total and partial ultrasound responders frequency of distribution.

Change in number of fistulas, pseudocysts and abscess as well as change in doppler activity. Defining total ultrasound responders as the ones that have a smaller number of pseudocysts, liquid collections, fistulas, smaller size and thickness of the main injury and less doppler activity than the registered in the baseline ultrasound and partial ultrasound responders as the ones that have less activity than in the baseline ultrasound in at least one of the previous variables without increase in any of the others.